Abstract: Described herein are systems, method, and non-transitory computer-readable media employing provisional nodal addresses and refined nodal addresses to assist health care providers in guiding treatment decisions and to provide an expected outcome for a patient diagnosed with a disease.

Abstract: The described invention provides methods for detecting, diagnosing and treating low-grade ovarian cancer and stage I ovarian cancer by comparing results from serum and ovarian tissue samples with normal controls. An increased level of expression of serine protease, wherein the serine protease is at least 2 selected from the group consisting of kallikrein 6 (KLK6), kallikrein 7 (KLK7), and PRSS8, expressed by subject samples compared to the level of expression of serine protease expressed by normal control samples is indicative of possible early stage ovarian cancer in the subject. Once early stage (I/II) ovarian cancer is diagnosed, the subject is treated with a treatment regimen effective to treat the early stage (I/II) ovarian cancer.

Abstract: The described invention provides methods for irradiating skin cancer cells, such as melanoma cells, at a high radiation rate (e.g., of 2,400 mu/min) and a modest total dose (e.g., of 0.5 Gy) to treat skin cancer or induce apoptosis in skin cancer cells. The radiation may be administered in a plurality of treatments and used in conjunction with chemotherapy.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: CNA-guided care, which can improve clinical outcomes at a specific patient level and decrease total cost of care at the population level, has two faces. The first face, the enabling tool, allows a payer to transmit information identifying a health care service under consideration for a patient with a health condition whose health plan benefits cover the service and other payer-selected variables. In response, the payer receives information sufficient to establish that the medical service is an appropriate delivery or level of service allowing the payer to approve payment to a medical care provider for the service. The second face provides for communications that provide information sufficient for a complete medical evaluation and for assigning a CNA to the patient. The patient then can use the assigned CNA to select an optimal care plan and a medical professional based on patient-set criteria within the CNA.

Abstract: The described invention provides a method, system and non-transitory computer readable medium storing computer program instructions for enabling a patient with a condition to optimize treatment options based on geography, clinical outcome, cost and other patient-set criteria.

Abstract: The described invention provides a method, a system and non-transitory computer readable medium storing computer program instructions that when executed on a processor cause communicatively linked clinical outcome tracking and analysis modules to perform operations that use CNA-guided care to improve clinical outcomes at a specific patient level and to decrease total cost of care at the population level.

Abstract: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. The method treats ongoing vascular insufficiency affecting coronary circulation by (i) stimulating neoangiogenesis in a peri-infarct border zone, thereby improving myocardial perfusion; and, (ii) through a paracrine effect, preventing apoptosis of cardiomyocytes in the peri-infarct border zone. The neoangiogenesis and paracrine-mediated reduction of apoptosis reduces progressive myocardial cell loss, which leads to improvement in cardiac function and a reduction of risk of major adverse cardiovascular events.

Abstract: The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The described invention provides a method, system and non-transitory computer readable medium storing computer program instructions for enabling a patient with a condition to optimize treatment options based on geography, clinical outcome, cost and other patient-set criteria.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The described invention provides methods for detecting, diagnosing and treating low-grade ovarian cancer and stage I ovarian cancer by comparing results from serum and ovarian tissue samples with normal controls. An increased level of expression of serine protease, wherein the serine protease is at least 2 selected from the group consisting of kallikrein 6 (KLK6), kallikrein 7 (KLK7), and PRSS8, expressed by subject samples compared to the level of expression of serine protease expressed by normal control samples is indicative of possible early stage ovarian cancer in the subject. Once early stage (I/II) ovarian cancer is diagnosed, the subject is treated with a treatment regimen effective to treat the early stage (I/II) ovarian cancer.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The described invention provides a system and method for clinical outcome tracking and analysis. The clinical outcome tracking and analysis comprises sorting, outcome tracking, quality of life metrics, toxicity to therapy and cost of care. The system and method includes receiving one or more parameters. Exemplary parameters for sorting include sex, age, ethnicity, comorbidities, tobacco use, source of insurance, medical record number, primary care physician, referring physician, hospital, approved service vendors, disease-specific clinical molecular phenotype, therapy intent, stage of therapy, biomarkers, and cost of care. A plurality of patient medical records are sorted, by a clinical outcome tracking and analysis module executed by a processor, to provide a set of patient medical records satisfying the one or more parameters.

Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.

Abstract: The described invention provides cellular therapeutic approaches for treating a vascular insufficiency following a traumatic injury to head or spine that results in an injury to brain, spinal cord, or both by administering a therapeutic amount of an isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4 cells that have CXCR-4-mediated chemotactic activity.

Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.